References
- Aaltomaa S, Lipponen P, Syrjanen K (1993). Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer. Anticancer Res, 13, 533-8.
- Cianfrocca M, Goldstein LJ (2004). Prognostic and predictive factors in early-stage breast cancer. Oncologist, 9, 606-16. https://doi.org/10.1634/theoncologist.9-6-606
- Ellis MJ, Coop A, Singh B, et al (2001) . Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol, 19, 3808-16.
- Faneyte IF, Peterse JL, Van Tinteren H, et al (2004) . Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res, 10, 4457-63. https://doi.org/10.1158/1078-0432.CCR-03-0054
- Ferrero-Pous M, Hacene K, Bouchet C, et al (2000) . Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res, 6, 4745-54.
- Fisher B, Bauer M, Wickerham DL, et al (1983) . Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer, 52, 1551-7. https://doi.org/10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3
- Gianni L, Dafni U, Gelber RD, et al (2011) . Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol, 12, 236-44. https://doi.org/10.1016/S1470-2045(11)70033-X
- Le Doussal V, Tubiana-Hulin M, Friedman S, et al (1989) . Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer, 64, 1914-21. https://doi.org/10.1002/1097-0142(19891101)64:9<1914::AID-CNCR2820640926>3.0.CO;2-G
- Menard S, Balsari A, Casalini P, et al (2002) . HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res, 8, 520-5.
- Moliterni A, Menard S, Valagussa P, et al (2003) . HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol, 21, 458-62. https://doi.org/10.1200/JCO.2003.04.021
- Romond EH, Perez EA, Bryant J, et al (2005) . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 1673-84. https://doi.org/10.1056/NEJMoa052122
- Nemoto T, Natarajan N, Bedwani R, et al (1983) . Breast cancer in the medial half. Results of 1978 National Survey of the American College of Surgeons. Cancer, 51, 1333-8. https://doi.org/10.1002/1097-0142(19830415)51:8<1333::AID-CNCR2820510802>3.0.CO;2-T
- Neville AM, Bettelheim R, Gelber RD, et al (1992) . Factors predicting treatment responsiveness and prognosis in nodenegative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol, 10, 696-705.
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al (2005) . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1659-72. https://doi.org/10.1056/NEJMoa052306
- Polychemotherapy for early breast cancer: an overview of the randomised trials (1998) . Early Breast Cancer Trialists' Collaborative Group. Lancet, 352, 930-42. https://doi.org/10.1016/S0140-6736(98)03301-7
- Revillion F, Bonneterre J, Peyrat JP (1998) . ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer, 34, 791-808. https://doi.org/10.1016/S0959-8049(97)10157-5
- Rosen PP, Groshen S, Saigo PE, et al (1989) . Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol, 7, 1239-51.
- Ross JS, Fletcher JA (1998) . The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist, 3, 237-52.
- Slamon DJ, Eiermann W, Robert N, et al (2005) . Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel(ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab(ACTH) with docetaxel, carboplatin and trastuzumab(TCH) in her2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res and Treat, 94, S5.
- Sledge GW Jr, Miller KD (2003) . Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer, 39, 1668-75. https://doi.org/10.1016/S0959-8049(03)00273-9
- Tahan SR, Neuberg DS, Dieffenbach A, et al (1993) . Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer, 71, 3552-9. https://doi.org/10.1002/1097-0142(19930601)71:11<3552::AID-CNCR2820711115>3.0.CO;2-N
- Tamoxifen for early breast cancer: an overview of the randomised trials (1998). Early Breast Cancer Trialists' Collaborative Group. Lancet, 351, 1451-67. https://doi.org/10.1016/S0140-6736(97)11423-4
- Tang ZY (2000). Contemporary Oncology 2nd Ed. Shanghai Medical University Press, 2000.
- Traina A, Agostara B, Marasa L, et al (2006) . HER2/neu expression in relation to clinicopathologic features of breast cancer patients. Ann N Y Acad Sci, 1089, 159-67. https://doi.org/10.1196/annals.1386.029
- Xia W, Chen JS, Zhou X, et al (2004). Phosphorylation/ cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res, 10, 3815-24. https://doi.org/10.1158/1078-0432.CCR-03-0527
- Yildirim E, Dalgic T, Berberoglu U (2000) . Prognostic significance of young age in breast cancer. J Surg Oncol, 74, 267-72. https://doi.org/10.1002/1096-9098(200008)74:4<267::AID-JSO5>3.0.CO;2-N
Cited by
- Predictive Factors for Supraclavicular Lymph Node Recurrence in N1 Breast Cancer Patients vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2509
- Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER vol.110, pp.11, 2014, https://doi.org/10.1038/bjc.2014.174
- Benefit of Post-mastectomy Radiotherapy of the Supra-/infraclavicular Lymphatic Drainage Area in Breast Cancer Patients vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5557
- Relation of Alcohol/Tobacco use with Metastasis, Hormonal (Estrogen and Progesterone) Receptor Status and c-erbB2 Protein in Mammary Ductal Carcinoma vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5709
- SLC35B2 Expression is Associated with a Poor Prognosis of Invasive Ductal Breast Carcinoma vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6065
- Overexpression of HER-2/neu in Patients with Prostatic Adenocarcinoma vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6425
- Investigation of Antitumor Effects of Sorafenib and Lapatinib Alone and in Combination on MCF-7 Breast Cancer Cells vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3185
- Predictive and Prognostic Significance of p27, Akt, PTEN and PI3K Expression in HER2-Positive Metastatic Breast Cancer vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2645
- Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer vol.159, pp.2, 2016, https://doi.org/10.1007/s10549-016-3933-6